Markets
Will the UK government announce updated guidance for managing polycystic ovary syndrome (PCOS) by August 31, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if the UK government, or the National Institute for Health and Care Excellence (NICE), officially announces updated guidance explicitly concerning the management of polycystic ovary syndrome (PCOS) by August 31, 2026. If no such announcement is made by that date, the market resolves to No. This market was prompted by *The Pharmaceutical Journal* reporting on the establishment of the first UK guidance for polyendocrine metabolic ovarian syndrome.
Rules
- Market closes at 8/31/2026.
- Logic weighted resolution applies.
The current price seems too low given the rising awareness around PCOS and its impact. More policymakers are likely to push for updated guidance, especially with recent studies showing better management options. What is the model pricing this, and are we considering the recent shifts in health policy?
Rationale:The comment is factually accurate regarding the rising awareness of PCOS and the potential for updated guidance, supported by recent studies. It logically addresses the market question and avoids major fallacies, though it leans slightly on emotional appeal regarding the urgency of the issue. The weights reflect the importance of factual accuracy and relevance in this context, given the discussion of health policy changes.
It seems pretty unlikely that the UK government will roll out any new guidance on PCOS in such a short timeframe. Given how slow the process typically is for healthcare policies, I wonder if the current odds reflect an overly optimistic view.
Rationale:The comment presents a reasonable skepticism regarding the timeline for new guidance on PCOS, which aligns with the typical pace of healthcare policy changes. While it lacks specific evidence to support the claim about the timeframe, it is logically sound and relevant to the market question. The weights reflect a balanced focus on relevance and logical reasoning, with some emphasis on factual accuracy given the context of healthcare policy processes.
I think there's a good chance the UK government will release updated guidance for managing PCOS by the end of August. They have been increasingly focused on women's health issues, and we saw recent efforts in other areas. However, the market seems overly confident; a 70% price might be too high. There are still significant discussions happening within the NHS about resources and approaches.
Rationale:The comment presents a mostly accurate assessment of the UK government's focus on women's health, which is supported by recent initiatives, but lacks specific evidence for the claim about updated guidance for PCOS. It directly addresses the market question and provides a logical critique of the market's confidence level. The weights reflect the importance of relevance and logical reasoning in this context, given the comment's analytical nature.
Current odds seem too low for this market. Given the increasing awareness around women's health issues, I expect some update from the UK government by the end of August. They issued new guidelines on similar health topics recently, which backs my expectation. I'd set the chance at around 70 percent, not the 50 percent range we're seeing now.
Rationale:The comment presents a mostly accurate expectation based on the increasing awareness of women's health issues and references recent government actions, which supports the claim. The logical reasoning is sound, with no significant fallacies detected, and it is relevant to the market question. The weights reflect the importance of factual accuracy and logical reasoning in this context, while emotional appeal is less significant.
Current prices suggest low confidence in an announcement, but the recent push for women's health initiatives in the UK could shift that. There's a strong base rate here, given the attention on PCOS lately. I'd expect at least a draft by the deadline.
Rationale:The comment accurately reflects the current market sentiment and acknowledges the recent focus on women's health, which is relevant to the question. However, while it suggests a strong base rate for an announcement, it lacks specific evidence to fully support the expectation of a draft by the deadline. The weights reflect a balanced emphasis on factual accuracy and relevance, with a slight lean towards logical reasoning given the context of the comment.
The current odds seem low for updated guidance on PCOS by the end of the month, but I think the recent push for women's health awareness could change that. With more research coming out and discussions in Parliament, I’d estimate a 60% chance of an announcement. However, if they follow the usual patterns of delays in health policy, this might fall short. What are others thinking?
Rationale:The comment provides a reasonable estimate of the likelihood of an announcement based on current trends and discussions, which is mostly accurate but lacks specific evidence for the 60% estimate. It addresses the market question directly and avoids major logical fallacies, though it does include some emotional appeal regarding women's health awareness. The weights reflect a balanced focus on relevance and logical reasoning while acknowledging the need for factual support.
It seems unlikely the UK government will have updated guidance by then, given how slow these processes tend to be; it's worth considering if the price reflects that.
Rationale:The comment presents a reasonable perspective on the likelihood of the UK government updating guidance by the specified date, which aligns with known bureaucratic processes. It avoids logical fallacies and remains relevant to the market question, though it could benefit from more specific evidence or examples to strengthen its factual basis. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the speculative nature of the comment.
honestly, I think the likelihood of the UK government updating PCOS guidelines by the end of August is pretty slim. we haven’t seen a major update since 2018, and with how slow government bodies can be, it feels like this might get pushed again. plus, there’s a lot of funding issues in healthcare right now, and they probably have other priorities. some might argue the rise in awareness could urge them to act, but I’m not convinced. at this price, I think it's overvalued. just my two cents.
Rationale:The comment presents a mostly accurate assessment of the situation regarding PCOS guidelines, noting the lack of updates since 2018 and potential funding issues, which supports a moderate score for Fact Check. It logically addresses the market question and provides a personal opinion on valuation, but it does contain some emotional elements. The weights reflect the importance of relevance and logical reasoning in this context, while still considering factual accuracy.
Honestly don't see why this market is so high, like what evidence is there that they’ll actually update guidelines anytime soon? Last change was ages ago in 2018 and they’ve been pretty slow to act on other health issues. Like, I'd buy at 30%, but at 50% seems like a stretch.
Rationale:The comment raises valid points about the lack of recent updates to guidelines, which is factually accurate, but lacks specific evidence to support the claim about the government's slow response. The comment is relevant to the market question and presents a logical argument, though it does contain some emotional appeal regarding the perceived stretch of the market price. The weights reflect a balanced focus on relevance and logical reasoning while acknowledging the need for factual support.
It seems unlikely that the government will put out new guidance by then; they usually take their time with health policies and this topic is not getting enough attention lately.
Rationale:The comment presents a reasonable perspective based on the historical behavior of the government regarding health policies, which is mostly accurate but lacks specific evidence to support the claim about the current attention on PCOS. The relevance to the market question is high, as it directly addresses the likelihood of new guidance being issued. The weights reflect a balance between factual accuracy and logical reasoning, with a slight emphasis on relevance due to the comment's direct connection to the market question.